Protocol summary

Study aim
Determining the effect of Budesonide nasal spray in comparison with Betamethasone nasal drops and Budesonide nebulizing suspension on sinonasal polyposis recurrence
Design
108 patients who underwent FESS are randomly assigned to three study groups (36 patients in each group). Patients in all three groups are given cephalexin and rinsing serum in the first two weeks and routine corticosteroid treatment up to one month after surgery. The first diagnostic endoscopy is done two weeks after surgery, and patients are given either drop, spray, or solution according to their treatment group. Then, after 1 and 6 months, re-endoscopy and Modified L K-SCALE are done and results are compared.
Settings and conduct
108 patients with sinonasal polyposis who underwent FESS in Taleghani-Hospital, Tehran are assigned to three treatment groups, including Budesonide nasal spray, Betamethasone nasal drops, and Budesonide nebulizing suspension, using blocked randomization method. Then, 1 and 6 months after surgery, study groups are compared for outcomes. Blindness is not possible in this study due to the nature of interventions.
Participants/Inclusion and exclusion criteria
Sinonasal polyposis patients who candidate for FESS, between 18 to 70 years old; Absence of underlying diseases, including CF, Wegener's, Kartagener, sarcoidosis, vasculitis, or rheumatic diseases; Patients with sinonasal polyposis confirmed by preoperative history, endoscopy, and CT-scan; Receiving no systemic corticosteroids for up to 4 weeks before surgery
Intervention groups
Patients are assigned to three groups, including Budesonide nasal spray (as standard treatment), Betamethasone nasal drops, and Budesonide nebulizing suspension.
Main outcome variables
VAS, patients’ self-satisfaction with the surgery results, degree of rhinosinusitis polyps, complications (frequency and degree of recurrence, dry nose, Epistaxis), need to revision

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20201021049095N1
Registration date: 2021-09-29, 1400/07/07
Registration timing: registered_while_recruiting

Last update: 2021-09-29, 1400/07/07
Update count: 0
Registration date
2021-09-29, 1400/07/07
Registrant information
Name
Najmeh Rajabi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 8806 4168
Email address
najmeh.rajabi@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-09-23, 1400/07/01
Expected recruitment end date
2021-11-21, 1400/08/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparative assessment of the effect of corticosteroid in three forms of Budesonide nasal spray, Betamethasone nasal drop, and Budesonide nebulizing suspension on sinonasal polyposis recurrence after the FESS
Public title
Comparison of the effect of Budesonide nasal spray, Betamethasone nasal drop, and Budesonide nebulizing suspension on sinonasal polyposis recurrence
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
FESS candidates with sinonasal polyposis patients between 18 to 70 years old
Exclusion criteria:
Absence of underlying diseases, including CF, Wegener's, Kartagener, sarcoidosis, vasculitis, or rheumatic diseases; Receiving no systemic corticosteroids for up to 4 weeks before surgery; ages below 18 or higher than 70 years olds
Age
From 18 years old to 70 years old
Gender
Both
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 108
Randomization (investigator's opinion)
Randomized
Randomization description
A total of 108 patients with the study inclusion criteria were randomly assigned to three groups of 36 patients, including Budesonide nasal spray as the standard treatment in comparison with two intervention groups of Betamethasone nasal drop, and Budesonide nebulizing suspension. To begin with, one of the letters A, B, C is considered for each treatment, and Random Allocation software is used to build random blocks. The software generates 18 different blocks with size 6, according to the total sample size of 108, the blocks size of 6, and considering 3 treatment groups. There are 6 blanks in each block in which the 3 letters A, B, and C are randomly combined in different sequences, assuming that each letter is repeated twice in each block. Thus, the software output is a list of 18 blocks, each of which has 6 blanks, which are filled with different sequences of A, B, and C (each letter is repeated twice in every single block). In other words, we have a total of 18 blocks, each of which has 2 locations for every study treatment. Finally, by completing the sampling, we reach 36 patients in each of groups A, B and, C. Next, each block is placed in separate envelopes, encoded from 1 to 18. To maintain the principles of allocation concealment, the physician is not aware of the sequence inside each envelope. The envelopes are given to someone outside the research team who informs the physician about assigning each patient to treatment groups during the study.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Shahid-Beheshti University of Medical Sciences
Street address
Qods city, Simaye-Iran St., MOHME
City
Tehran
Province
Tehran
Postal code
3848176941
Approval date
2021-03-15, 1399/12/25
Ethics committee reference number
IR.SBMU.MSP.REC.1399.782

Health conditions studied

1

Description of health condition studied
Sinonazal polyposis
ICD-10 code
J33.9
ICD-10 code description
Nasal polyp, unspecified

Primary outcomes

1

Description
recurrence
Timepoint
1 and 6 months after surgery
Method of measurement
Diagnostic endoscopy

2

Description
degree of recurrence
Timepoint
1 and 6 month after surgery
Method of measurement
Modified L K –SCALE endoscopy

3

Description
Visual Analog Scale (VAS) for scoring the symptoms of sinusitis and polyps
Timepoint
1 and 6 months post operation
Method of measurement
questioning from patients

4

Description
self rated satisfaction of surgery outcomes
Timepoint
1 and 6 months post surgery
Method of measurement
questioning from patients

5

Description
need to revision
Timepoint
1 and 6 months post surgery
Method of measurement
examination and questioning from patients

Secondary outcomes

1

Description
side effects including dryness and Epistaxis
Timepoint
1 and 6 months after surgery
Method of measurement
clinical examination

Intervention groups

1

Description
Intervention group: Betamethasone nasal drop 0.1%- Daroopakhsh Company (3 drops on each side of the nose, once per night). In addition, Cephalexin and Lavage serum are given to the patients in all groups during the first two weeks of treatment. As well, routine corticosteroid treatment is given to all groups for up to one month after surgery.
Category
Prevention

2

Description
Intervention group: Budesonide nebulizing suspension, with a dose of 0.25 mg/ml in BD form- AstraZeneca Company (every morning and night, ten series with a syringe inside each side of the nose). In addition, Cephalexin and Lavage serum are given to the patients in all groups during the first two weeks of treatment. As well, routine corticosteroid treatment is given to all groups for up to one month after surgery.
Category
Prevention

3

Description
Control group: Budesonide nasal spray, 32 mcg- Razavi Pharmaceutical Services Institute (1 puff per day on each side of the nose). In addition, Cephalexin and Lavage serum are given to the patients in all groups during the first two weeks of treatment. As well, routine corticosteroid treatment is given to all groups for up to one month after surgery.
Category
Prevention

Recruitment centers

1

Recruitment center
Name of recruitment center
Tehran Taleghani Hospital
Full name of responsible person
Najmeh Rajabi
Street address
Yaman St.
City
Tehran
Province
Tehran
Postal code
1985711151
Phone
+98 21 2243 2560
Email
taleghanihospital@sbmu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
research and technology executive of Shahid-Beheshti University of Medical Sciences
Street address
Yaman St.
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Email
info@sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Najmeh Rajabi
Position
student
Latest degree
Medical doctor
Other areas of specialty/work
Ear, Nose, and Throat
Street address
Taleghani Hospital, Yaman st.
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 2243 2560
Email
najmeh.rajabi@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Najmeh Rajabi
Position
student
Latest degree
Medical doctor
Other areas of specialty/work
Ear, Nose, and Throat
Street address
Taleghani Hospital, Yaman St.
City
Tehran
Province
Tehran
Postal code
1985711151
Phone
+98 21 2243 2560
Email
najmeh.rajabi@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Najmeh Rajabi
Position
student
Latest degree
Medical doctor
Other areas of specialty/work
Ear, Nose, and Throat
Street address
Taleghani Hospital, Yaman St.
City
Tehran
Province
Tehran
Postal code
1985711151
Phone
+98 21 2243 2560
Email
Najmeh.rajabi@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
All data could be shared after deleting the patients' names
When the data will become available and for how long
Since the beginning of the data collection
To whom data/document is available
Researchers in academic and scientific institutions
Under which criteria data/document could be used
Data could be shared if other researchers request it
From where data/document is obtainable
Najmeh Rajabi
What processes are involved for a request to access data/document
Sending email to the researcher
Comments
Loading...